Insights

Insights/ Insights/ Patients/ R&D/ Views and analysis

Capturing progress in haemophilia care

mike.hammerton@pharmaphorum.com disease awareness, haemophilia, healthcare, patient advocacy, patient experience, Portraits of Progress, R&D 0 Comment

If we look back just 70 years, the prognosis for patients with haemophilia was remarkably different to what

Capturing progress in haemophilia care

https://pharmaphorum.com/views-and-analysis/capturing-progress-in-haemophilia-care/

Insights/ R&D/ Views & Analysis/ Views and analysis

Osteoporosis treatment options – down to the bare bones

Ben Hargreaves biosimilars, biphosphonates, Evenity, monoclonal antibody treatment, musculoskeletal diseases, new therapies, non communicable diseases, Oregon Oesteoporosis Center, osteoporosis, pipeline 0 Comment

It is World Osteoporosis Day this month, and Ben Hargreaves takes a look at what treatment options look

Osteoporosis treatment options – down to the bare bones

https://pharmaphorum.com/views-and-analysis/osteoporosis-treatment-options-down-to-the-bare-bones/

Field of burning oil wells, Persian Gulf War

Insights/ R&D/ Views & Analysis/ Views and analysis

Gulf War Illness: How can disease modelling aid the search for a cure?

mike.hammerton@pharmaphorum.com disease modelling, Elsevier, Gulf War Illness, in silico modelling, misdiagnosis, research 0 Comment

Biological systems are hugely complex, with a staggering number of pathways interacting every millisecond. The downstream effects of

Gulf War Illness: How can disease modelling aid the search for a cure?

https://pharmaphorum.com/views-and-analysis/gulf-war-illness-how-can-disease-modelling-aid-the-search-for-a-cure/

Insights/ News/ R&D/ Top stories

Gilead rescinds orphan status request for COVID-19 drug

Richard Staines coronavirus, COVID-19, Gilead, market access, orphan, pricing, R&D 0 Comment

Gilead has rescinded its request for orphan status for its potential COVID-19 antiviral remdesivir amid a furore over

Gilead rescinds orphan status request for COVID-19 drug

https://pharmaphorum.com/news/gilead-rescinds-orphan-status-request-for-covid-19-drug/

Insights/ R&D/ Slider in whitepapers/ White Papers/ Whitepapers

How to craft responsive clinical trials that are designed for success

mike.smith@pharmaphorum.com clinical trials, Cytel, data 0 Comment

Without the right design, right data and right decisions, idealised clinical trial plans cannot be translated into blueprints

How to craft responsive clinical trials that are designed for success

https://pharmaphorum.com/r-d/how-to-craft-responsive-clinical-trials-that-are-designed-for-success/

Insights/ Market Access/ News/ News/ News/ Oncology/ R&D

Lilly moves Crohn’s drug into phase 3, faces safety setback in Japan

Richard Staines cancer, Eli Lilly, gastroenterology, safety, Sanofi 0 Comment

Eli Lilly has had a mixed few days, posting promising trial results for mid-stage Crohn’s disease drug mirikizumab,

Lilly moves Crohn’s drug into phase 3, faces safety setback in Japan

https://pharmaphorum.com/news/lilly-moves-crohns-drug-mirikizumab/

Insights/ News/ R&D

Genentech signs deal with Parvus to tackle inflammatory diseases

Richard Staines Parvus, Roche 0 Comment

Canada’s Parvus Therapeutics has signed a deal with Roche’s Genentech unit to develop, manufacture and market drugs for

Genentech signs deal with Parvus to tackle inflammatory diseases

https://pharmaphorum.com/news/genentech-signs-deal-with-parvus-to-tackle-inflammatory-diseases/

Debates & Insight/ Debates & Insight/ Debates & Insights/ Digital/ Insights/ Insights/ Insights/ Patients/ R&D/ White Papers/ Whitepapers

Understanding blockchain – a practical guide for life sciences companies

louise.bellamy@pharmaphorum.com Blockchain, Distributed Ledger Technology, DLT, SAP 0 Comment

Within the life science industry, uptake of blockchain is in the early stages, but with investment levels in

Understanding blockchain – a practical guide for life sciences companies

https://pharmaphorum.com/digital/insights-digital/understanding-blockchain-life-sciences/

Insights/ Partner content/ Press releases

Exclusive insight from experts in the lyophilization industry

Lyudmyla Durneva freeze-drying, lyophilization 0 Comment

SMi Group reports: Leaders in the lyophilization industry to share their expertise and knowledge at SMi’s 4th annual

Exclusive insight from experts in the lyophilization industry

https://pharmaphorum.com/partner-content/exclusive-insight-from-experts-in-the-lyophilization-industry/

1 2

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

Insights

Login